Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

Conditions

• Locally Advanced Epithelioid Hemangioendothelioma
• Metastatic Epithelioid Hemangioendothelioma
• Unresectable Epithelioid Hemangioendothelioma

Eligibility Criteria

Sex

ALL

Age

15 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Questionnaire Administration — OTHER
  Ancillary studies
• Trametinib — DRUG
  Given PO

Study Details

This phase II trial studies how well trametinib works in treating patients with epithelioid hemangioendothelioma that has spread to other places in the body (metastatic), nearby tissue or lymph nodes (locally advanced), or cannot be removed by surgery (unresectable). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date

Jun 20, 2017

Status verified

Nov 2024

Primary completion

Jun 23, 2023

Completion

Jun 23, 2023

Study Design

Enrollment

44 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (trametinib)
  Patients receive trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 52 cycles in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Objective Response Rate [ Time Frame: 6 months ]

Locations (36)

Find similar trials in Phoenix, AZ